NHC cuts red tape for clinics in FTZs



China’s National Healthcare Commission (NHC) released a notification on “Separating Operating Permits from Business Licenses” for free trade zones (FTZs) in Shanghai, Guangdong, Tianjin and others, effective December 1 2019. The measures are focused on reducing bureaucratic barriers in several ways, with particular impact on healthcare and medical industries.

Key takeaways include:

1. FTZs will not place restrictions on establishing clinics. Approvals, set-up, and registration will be supplanted by a filing management system.

2. Local healthcare administrations in the pilots will register clinics and focus will shift from equipment and hardware to physician qualifications and capabilities.

3. Physicians who have practiced in medical institutions for 5 years with intermediate or above qualifications are encouraged to operate specialist clinics, either full-time or part-time.

4. Local healthcare administrations involved in the pilots are encouraged to include clinics while establishing urban medical groups and county medical communities, and to set up referral systems between clinics and other medical institutions.

5. Various specialist physicians are encouraged to set up groups and partnerships and open joint specialist clinics.

6. Clinics that proactively implement price policy of medical services in public medical institutions and meet certain requirements will be eligible for coverage under the national medical insurance schemes.

7. Review, approval and registration will be combined into one process for setting up new medical institutions other than Class 3 general hospitals, Class 3 maternal and child health hospitals, emergency centers, emergency stations, clinical testing centers, Chinese-foreign joint venture co-operative medical institutions, and Hong Kong, Macao and Taiwan wholly-owned medical institutions.

Reference:

Related news
China’s national drug use monitoring platform, online since November 25, now covers a network of 8,840 medical institutions and is handling an average 600,000 person visits daily, according to the National Healthcare Commission (NHC).
China’s National Healthcare Commission (NHC) released guidelines guiding clinics and hospitals providing respiratory care.
China’s National Healthcare Commission (NHC) released notice that a selection of hospitals will be chosen to pilot enhanced recovery after surgery (ERAS) during the rest of this year and into 2020.
China’s National Healthcare Commission (NHC) released four new guidelines setting hospital clinical standards and interventional treatment guidance for cardiovascular and neurovascular diseases.
China’s National Healthcare Commission (NHC) issued the "Large Hospital Inspection Work Plan (2019-2022)", indicating that a new round of inspections at large public hospitals will be kicked off.
Recent news
Chile’s Ministry of Health (MINSAL) this week announced measures against gender and age inequalities regarding Welfare Health Institutions (ISAPREs) fees.
Brazil-based Biolab, the leading seller of cardiology medicines in the Brazilian market, has signed an agreement with France-based Quantum Genomics to partner on the development, production, and commercialization in Latin America of a novel treatment for hypertension.
According to preliminary data from Mexico’s 2018 National Health and Nutrition Survey (ENSANUT), chronic diseases have continued to increase in the country since the previous survey in 2012.
Shandong province is set to scrap mark-ups on medical consumables at public medical institutions, according to a document released by the province.
US-based AbbVie’s Bruton’s tyrosine kinase (BTK) inhibitor ABBV-105 and Janus kinase 1 (JAK1) inhibitor upadacitinib (trade name: Rinvoq) have both won clinical trial approvals from the Center for Drug Evaluation (CDE).
China’s national drug use monitoring platform, online since November 25, now covers a network of 8,840 medical institutions and is handling an average 600,000 person visits daily, according to the National Healthcare Commission (NHC).
US-based biotech Amgen (Nasdaq.AMGN) trumpeted a new indication approval for its PCSK9 inhibitor Repatha (evolocumab) in China.
Analytics Snapshot


Analytics Snapshot